Global adoption Medimaps has a strong international footprint with 90 countries using TBS Osteo and over 4.5 million procedures annually, indicating ample opportunity to expand in markets where bone health imaging is routine.

Reimbursement milestone Medimaps achieved Medicare reimbursement in the USA for TBS Osteo under Category 1 in January 2022, signaling credibility with payers and a potential lever to pursue additional payer coverage and adoption in the US market.

New product expansions The launch of TBS Reveal at RSNA 2025 demonstrates ongoing product innovation in AI-driven bone imaging, presenting upsell paths for existing customers and entry points to new facilities seeking advanced analytics.

Workflow integration Founded to integrate seamlessly into clinicians’ workflows, Medimaps can target hospitals and clinics looking to replace or augment current imaging workflows with AI-enhanced bone microarchitecture assessment.

Mid-market focus With a revenue range of one to several million and an employee base under 200, Medimaps sits in a mid-market niche where targeted partnerships with mid-sized radiology groups and regional distributors could accelerate adoption and scale.